05:06 AM EDT, 10/16/2026 (MT Newswires) -- UCB (UCB.BR) received approval from the US Food and Drug Administration for the autoinjector administration option for Zilbrysq in adults with generalized myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The once-daily autoinjector automatically delivers a pre-defined dose to simplify self-administration, the Brussels-listed biopharmaceutical company said Friday. Zilbrysq, or zilucoplan, was previously available as a self-administered prefilled syringe. UCB expects the autoinjector to be available in the first quarter of 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.